DSAP patients could benefit from new psoriasis drugs or any drug that aims to "normalize" skin. The trouble is that probably nobody cares or is making any effort to get DSAP patients involved with psoriasis drug studies. It's up to us to try to take action. Why wait? Call these companies to see if you can be their guinea pig! Let me know if any let you participate! Click to email me

I subscribe to a newsletter published by the National Psoriasis Foundation. In the September/ October 2000 issue I found this detailed list of new drug treatments being researched.

NPF says that the most promising psoriasis drugs are Amevive and hu1124 which I have highlighted in blue below.

Drug Name

Company

Description

Status

5G1.1

Alexion Pharmaceuticals

anti-inflammatory complement inhibitor drug candidate

phase 1b

9906

Stiefel

topical cream

phase 2

ABX-IL8

Abgenix

anti-IL8 antibody

phase 2

Amevive (alefacept)

Biogen

fussion protein that binds to CD2 receptor on T cells

phase 3

Anti-IGF antisense oligo-nucleotide

Centre for Hormone Research (Australia)

blocks IGF, epidermal growth regulator

preclinical

BCI 202

Bone Care International

vitamin D analogue

preclinical

BCX34

Biocryst

blocks enzyme (PNP) needed for T-cell division (topical)

phase 2

Clenoliximab

SmithCline Beecham

anti CD4 MaB

phase 1

Combretastatin A4 Prodrug (CA4P)

OXiGENE, Inc.

anti-angiogenesis drug

phase 1

EGFR & VEGFR inhibitors

OSI-Pfiser

small molecule inhibitors

preclinical

Enbrel (etanercept)

Immunex/Wyeth-Ayerst

anti-TNF(tumor necrosis factor) drug

phase 3

hu1124 (anti-CD11a)

Genentech / XOMA 1(888)662-6728

humanized monoclonal antibody against T-cell receptor.

phase 3

ICM3

ICOS

monoclonal antibody that blocks ICAM-3

phase 1/2

IDEC-114

IDEC Pharmaceuticals

monoclonal antibody designed to bind with B7 receptor on antigen presenting cells

phase 1/2

IPL4323

Inflazyme

oral antinflammatory

preclinical

IR502

Immune Response

causes the immune system to shut down activated T-cells

phase 2

ISIS 2302

ISIS

inhibits ICAM-I (topical)

phase 2a

LTD-Z-92

Psoraya Pharmaceuticals

plant-based topical epidermal keratinocyte antiproliferative

phase 1/2

MEDI-507

Medimmune

anti-CD2 humanized monoclonal intibody. Study coordinator is Mark Guirrieri (602)437-0097

phase 1 complete

Mycophenolate mofetil (CellCept)

Hoffmann-La Roche

systemic immunosuppressant

investigator initiated trails only

Neovastat (AE-941)

Aeterna

angiogenesis inhibitor

phase 1/2 completed

Olux

Connetics

steroid (clobetasol propionate) foam

FDA approved May 2000

Ontak (DAB3891L2)

Ligand Pharmaceuticals

IL-2 fusion toxin

phase 1/2

Oral Tazarotene

Allergan

Vitamin A derivative

phase 2

Paclitaxel

Angiotech Pharmaceuticals

anti-cancer drug (topical)

phase 1/2

Panretin (alitretinoin)

Ligand Pharmaceuticals

oral vitamin A derivative

phase 2

Panretin (alitretinoin)

Ligand Pharmaceuticals

topical gel, vitamin A derivative

phase 4

Peptide T

Advanced Immuni T

immunomodulator

phase 1/2

PH-10

Photogen Technologies, Inc

light sensitizer used with green lights

phase 1

Psorgon

Nascent Pharmaceuticals

(2,5 methyldiethylcinnamate)

preclinical

PVAC

Corixa 

injectable immunomodulatory agent. California 415-476-4701

phase 2

Remicade (infliximab)

Centocor

anti-TNF (tumor necrosis factor) drug

approved for Crohn's disease and Rheumatoid arthritis

SB 33 2235

SmithKline Beecham

oral IL-8 antagonist

preclinical

Simulect

Novartis

blocks IL-2 receptors; transplant drug

phase 1

SMART Anti-CD3

Protein Design Labs

humanized antibody

phase 1/2

ST630

Penederm

topical vitamin D derivative

phase 1 completed

Targretin (bexarotene)

Ligand Pharmaceuticals

oral vitamin A derivative

phase 2

Tenovil (rhulL10)

Schering

increases levels of IL-10

phase 2

VAS972

Vasogen

immunomodulator treats blood removed from body in a medical device and returns it to the body.

phase 1/2

VX148

Veertex

inhibits IMPDH, which may block T cell proliferation

preclinical

Zenapax

Protein Design Labs

SMART anti-TAC humanized antibody

phase 2

 

Phases of drug developement
Preclinical: Extensive laboratory and animal testing by companies to determine biological activity and safety.
Investigational New Drug (IND) application: Describes results of preclinical testing; filed by companies with the FDA prior to initiating testing in people. The IND becomes effective if the FDA does not reject it within 30 days.
Phase 1 clinical trials: Dosing study to establish safe dosage range and to determine how the drug is processed by the body.
Phase 2: Controlled testing to assess effectiveness and safety.
Phase 3: Extensive testing in clinics and hospitals to confirm effectiveness and side effects from use.
New Drug Application (NDA): Files with the FDA after completion of human clinical trials. An NDA usually contains hundreds of thousands of pages of scientific information and clinical data. 

GO BACK